<DOC>
	<DOCNO>NCT00403130</DOCNO>
	<brief_summary>Single-institution phase 2 trial investigate efficacy capecitabine , oxaliplatin bevacizumab patient metastatic neuroendocrine tumor .</brief_summary>
	<brief_title>Phase 2 Study Gemzar , Taxol &amp; Avastin Combination 1st Line Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description>This study evaluate time-to-progression ( TTP ) patient metastatic breast cancer , receive 1st line therapy bevacizumab combination paclitaxel gemcitabine . Secondary objective include response rate overall survival ( OS ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>INCLUSION CRITERIA Previouslyuntreated metastatic breast cancer . May prior chest wall irradiation palliative radiation bony site control pain fracture . These site disease , however , consider site measurable disease . Use bisphosphonates permit . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Granulocyte count ≥ 1500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL . Serum glutamic oxaloacetic transaminase ( SGOT ) / serum glutamic pyruvic transaminase ( SGPT ) ≤ 2.5 x institutional upper limit normal ( ULN ) alkaline phosphatase ≤ ULN alkaline phosphatase may 4 x ULN transaminases ≤ ULN . Total bilirubin within institutional limit normal . Calculated creatinine clearance ≥ 30 mL/min use formula : Ccr ( mL/min ) = [ ( 140age year ) X ( wt kg ) X 0.85 ( female ) ] / ( 72 x serum creatinine mg/dL ) ≥ 18 year age . Prior anthracycline treatment adjuvant set prior chest wall radiation must leave ventricular ejection fraction ( LVEF ) within institutional range normal assessed pretreatment multigated acquisition ( MUGA ) scan echocardiogram ( ECHO ) . All patient must give sign write informed consent . May receive adjuvant therapy long therapy complete &gt; 12 month study entry . Females childbearing potential must negative pregnancy test take ≤ 2 week prior study enrollment , must consent use effective contraception study period 6months thereafter . EXCLUSION CRITERIA Receiving hormonal therapy Prior treatment metastatic disease cytotoxic agent inhibitor epidermal growth factor receptor ( EGFR ) Her2NEUpositive breast cancer , either immunohistochemistry ( IHC ) score 3+ fluorescence situ hybridization ( FISH ) Pregnant lactate . Patients active malignancy breast cancer past 5 year exception situ carcinoma cervix nonmelanomatous skin cancer . Active unresolved infection . Preexisting peripheral neuropathy &gt; Grade 1 . Prior history severe hypersensitivity reaction paclitaxel , gemcitabine , bevacizumab drug formulate polysorbate 80 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . Blood pressure &gt; 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction within 6 month History stroke within 6 month Clinicallysignificant peripheral vascular disease Evidence bleed diathesis coagulopathy Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 Urine protein : creatinine ratio ≥ 1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Inability comply study and/or followup procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>